DR
Therapeutic Areas
Debiopharm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Debio 4126 | Oncology (Sustained Proliferative Signaling) | Phase 3 |
| zedoresertib (Debio 0123) | Oncology (Genome Instability) | Phase 2 |
| lunresertib (Debio 2513) | Oncology (Genome Instability) | Phase 2 |
| Debio 1562M | Oncology (anti-CD37 ADC) | Phase 1/2 |
| Debio 2512 | Oncology (HER3-HER2 ADC) | Phase 1 |
| Debio 2511 | Oncology (Undisclosed ADC) | Preclinical |
| Debio 0633 | Oncology (Undisclosed ADC) | Preclinical |